Cardiac electrophysiology

BIOTRONIK Announces FDA Approval of Renamic Neo with LiveSupport Software

Retrieved on: 
화요일, 4월 26, 2022
Workflow, ICDS, Food, Hospital, Cardiac electrophysiology, Mark (given name), Heart, Health, Human body, EHR, Food and Drug Administration, LCD, Section, FDA, Medical device, Video game console

In addition to its programming functions, Renamic Neo now offers LiveSupport, which allows clinicians to share the programmer screen with, or grant programmer control to, BIOTRONIK technical support personnel at remote locations.

Key Points: 
  • In addition to its programming functions, Renamic Neo now offers LiveSupport, which allows clinicians to share the programmer screen with, or grant programmer control to, BIOTRONIK technical support personnel at remote locations.
  • Renamic Neo is also compatible with BIOTRONIK's ReportShare and EHR DataSync to allow secure and easy integration of programmer data into hospitals' EHR systems.
  • The Renamic Neo programmer boasts a 12" high-resolution, high-contrast, LCD touch screen display, a built-in analyzer, and battery-powered portability, as well as various connectivity options.
  • Renamic Neo will soon be available in the United States to hospitals and clinics that implant BIOTRONIK cardiac rhythm management devices.

BioSig to Present at Heart Rhythm 2022

Retrieved on: 
화요일, 4월 19, 2022
Online, Medicine, EP, Workflow, Mayo Clinic, Wiley (publisher), U.S. Securities and Exchange Commission, COVID-19, Security (finance), Risk, St Davids, NASDAQ, Research, POD, CA, Heart Rhythm Society, Software, GLOBE, Education, Patient, Decision-making, Arrhythmia, Saint David, Harmonic, Moscone Center, Company, SEC, Journal, Cardiac electrophysiology, Electrophysiology, Massachusetts General Hospital, Nautilus, Inc. v. Biosig Instruments, Inc., Physician, HRS, FDA, Journal of Cardiovascular Electrophysiology, Medical Center, PURE, Heart Rhythm, Pharmaceutical industry, Medical device

Westport, CT, April 19, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (BioSig or the Company) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that the Company would be exhibiting at Heart Rhythm 2022, due to take place on April 29 May 1, 2022 at the Moscone Center in San Francisco, CA.

Key Points: 
  • Westport, CT, April 19, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (BioSig or the Company) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that the Company would be exhibiting at Heart Rhythm 2022, due to take place on April 29 May 1, 2022 at the Moscone Center in San Francisco, CA.
  • The presentation session will take place at Pod #12 on Sunday May 1st, 2022.
  • Heart Rhythm 2022 is a hub for innovation and discoveries in medicine.
  • Heart Rhythm 2022 is Heart Rhythm Society program.

BioSig to Present at NobleCon18 Capital Markets Conference

Retrieved on: 
목요일, 4월 7, 2022
Online, Electrophysiology, Company, Hard Rock Cafe, PURE, Journal, Catalog, NASDAQ, Saint David, Journal of Cardiovascular Electrophysiology, Cardiac electrophysiology, ECG, Risk, Medical Center, Massachusetts General Hospital, Wiley (publisher), Research, SEC, Conference, Webcast, FINRA, Decision-making, U.S. Securities and Exchange Commission, Capital market, EP, Mayo Clinic, Hard Rock Hotel & Casino Atlantic City, Workflow, COVID-19, GLOBE, Physician, St Davids, Nautilus, Inc. v. Biosig Instruments, Inc., FDA, FREE, Patient, Security (finance), Pharmaceutical industry, Noble

Conference attendees will also have the opportuntity to meet BioSig management during breakout sessions scheduled for 1:00 PM ET on Wednesday April 20, 2022.

Key Points: 
  • Conference attendees will also have the opportuntity to meet BioSig management during breakout sessions scheduled for 1:00 PM ET on Wednesday April 20, 2022.
  • A replay of the presentation will be available the following day on the BioSig Website .
  • The presentation will be part of a complete catalog of presentation available at Noble Capital Markets Conference website and on Channelcheck [ www.channelcheck.com ] the investor portal created by Noble.
  • Noble Capital Markets (Noble) is a research driven investment bank that has supported small & microcap companies since 1984.

Aziyo Announces FDA 510(k) Submission for CanGaroo® RM, its Next-Generation Biomaterial Envelope Enhanced with Antibiotics

Retrieved on: 
월요일, 4월 4, 2022
Company, Risk, Cardiac electrophysiology, Penn Presbyterian Medical Center, Forward-looking statement, Skin, SEC, Environment, Defibrillation, IED, U.S. Securities and Exchange Commission, Food, Neurostimulation, Review, Securities Exchange Act of 1934, Securities Act of 1933, Rifampicin, COVID-19, Projection, Regulation of tobacco by the U.S. Food and Drug Administration, GLOBE, Extracellular matrix, Drug Quality and Security Act, Awareness, FDA, Patient, Security (finance), Medical device, Minocycline

With this 510(k) submission, the Company intends to bring to the U.S. market a version of its existing FDA-approved CanGaroo envelope enhanced with the antibiotics Rifampin and Minocycline in dissolvable polymer rings.

Key Points: 
  • With this 510(k) submission, the Company intends to bring to the U.S. market a version of its existing FDA-approved CanGaroo envelope enhanced with the antibiotics Rifampin and Minocycline in dissolvable polymer rings.
  • The addition of antibiotics to the biomaterial envelope is designed to reduce the risk of bacterial colonization.
  • The CanGaroo Envelope is a pouch for cardiac implantable electronic devices and neurostimulators designed to stabilize the IED devices.
  • CanGaroo Envelope is comprised of small intestine submucosa derived extracellular matrix, a biomaterial which promotes a natural healing response resulting in healthy vascularized tissue.

Late-breaking data at ACC.22 with over 1 million patients demonstrates a major gap in guideline adherence resulting in higher mortality for patients with infected CIEDs

Retrieved on: 
월요일, 4월 4, 2022
Consensus, Risk, Lead, Duke University, Veni, vidi, vici, Greenspan, Anguera, HRS, NYSE, Caregiver, Research, Duke University School of Medicine, AEX, Electrophysiology, American College, Extraction, Solution, Education, PHG, Lexicon, Diagnosis, Mortality, CMS, Infection, Centers for Medicare & Medicaid Services, Senior, Quality of life, ESCMID, ACC, Cardiac electrophysiology, Death, Lead management, Awareness, American College of Cardiology, Journal of the American College of Cardiology, Internal medicine, European Heart Rhythm Association score of atrial fibrillation, Assistant, Safety, Physician, Pharmaceutical industry, Medical device, Medicare, Medicine, Patient

This study highlights the life-threatening nature of device infections and the significant opportunities to improve care in these complex patients.

Key Points: 
  • This study highlights the life-threatening nature of device infections and the significant opportunities to improve care in these complex patients.
  • The opportunity to ensure all patients have access to guideline-recommended care is not only imperative, but life-saving for patients across the world.
  • Each year one million CIEDs are implanted worldwide [4] (which include pacemakers, implantable cardioverter-defibrillators and cardiac resynchronization devices).
  • Low Rates Of Guideline Directed Care Associated With Higher Mortality In Patients With Infections Of Pacemakers And Implantable Cardioverter Defibrillators.

BioSig Technologies, Inc. Partners with Summit Blue Capital to Provide Equipment Leasing Services

Retrieved on: 
화요일, 3월 29, 2022
Online, Company, Electrophysiology, Journal, PURE, Saint David, Journal of Cardiovascular Electrophysiology, Partnership, Cardiac electrophysiology, ECG, Risk, Medical Center, Massachusetts General Hospital, Summit, Wiley (publisher), SEC, Program, Decision-making, CEO, U.S. Securities and Exchange Commission, United, EP, Mayo Clinic, Technology, Friction, Nasdaq, COVID-19, GLOBE, Physician, St Davids, Solution, Nautilus, Inc. v. Biosig Instruments, Inc., Annual report, FDA, Patient, Security (finance), Pharmaceutical industry

The Minneapolis-based Summit Blue Capital is a leader in equipment finance and leasing.

Key Points: 
  • The Minneapolis-based Summit Blue Capital is a leader in equipment finance and leasing.
  • Most notably, Summit Blue Capital specializes in simplifying the financing experience and finding solutions to advance commercial roll outs in the healthcare industry.
  • "We believe that partnering with Summit Blue Capital will have considerable benefits to our commercial plans.
  • The team at Summit Blue Capital is expected to also help us launch a subscription-based revenue model for our software.

BioSig Technologies, Inc. Appoints John Sieckhaus as Chief Operating Officer

Retrieved on: 
수요일, 3월 16, 2022
Online, Abbott, SEC, Decision-making, PURE, CALA, Solution, Risk, GLOBE, Annual report, Johns Hopkins University, Patient, Electrophysiology, Hospital, FDA, Nasdaq, Massachusetts General Hospital, COVID-19, St Davids, EP, Biomedical engineering, Nautilus, Inc. v. Biosig Instruments, Inc., Senior, ABT, Wiley (publisher), Security (finance), Saint David, Journal, ECG, Medical Center, Company, St. Jude Medical, Mayo Clinic, General officer, CEO, Arrhythmia, Abbott Laboratories, NYSE, Biomedicine, Physician, U.S. Securities and Exchange Commission, Journal of Cardiovascular Electrophysiology, Cardiac electrophysiology, Pharmaceutical industry

Westport, CT, March 16, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the appointment of John Sieckhaus as Chief Operating Officer.

Key Points: 
  • Westport, CT, March 16, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the appointment of John Sieckhaus as Chief Operating Officer.
  • Mr. Sieckhaus brings to the Company 30 years in the healthcare industry, including 21 years at St. Jude Medical and Abbott Laboratories [NYSE: ABT].
  • Mr. Sieckhaus holds a Bachelor of Science degree in Biomedical Engineering from Johns Hopkins University.
  • Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov.

Implicity Hosts US Research Competition for Free Access to Advanced AI-powered Cardiac Remote Monitoring Platform

Retrieved on: 
목요일, 3월 10, 2022
Heart, Industry, Degenerative disease, Physician, Research, Cardiac electrophysiology, ILR, RM, Academic health science centre, ENG, Health, Adoption, Arrhythmia, CI, Doctor of Philosophy, Patient, Fortis Healthcare, Solution, CEO, Diagnosis, Algorithm, Medical device, IEEE Society on Social Implications of Technology

CAMBRIDGE, Mass., March 10, 2022 /PRNewswire/ -- Implicity , a leader in AI-powered remote patient monitoring and cardiac data management solutions, today announced an invitation for US-based researchers who are looking to conduct a study in the field of Cardiac Rhythm Management to apply for free access to Implicity's cardiac remote monitoring software, including the ILR ECG Analyzer & Advanced Research Tool.

Key Points: 
  • CAMBRIDGE, Mass., March 10, 2022 /PRNewswire/ -- Implicity , a leader in AI-powered remote patient monitoring and cardiac data management solutions, today announced an invitation for US-based researchers who are looking to conduct a study in the field of Cardiac Rhythm Management to apply for free access to Implicity's cardiac remote monitoring software, including the ILR ECG Analyzer & Advanced Research Tool.
  • "Research is at the heart of what we do at Implicity.
  • Cardiac remote monitoring has already been shown to reduce the number of unnecessary emergency department visits and improve the time to diagnose clinical events.
  • Winners receive free access to Implicity's AI-powered Cardiac Remote Monitoring platform and features, including the ILR ECG Analyzer and the Advanced Research Tool module, for a minimum of 12 months.

Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial

Retrieved on: 
월요일, 2월 7, 2022
People, Department, Time, Cleveland Clinic, Metal electrode leadless face, Heart, Heart rate, PMID, Technology, Patient, NYSE, Parenteral nutrition, Lead, Life, Health, Physician, DDD, Muscle tissue, Cardiac electrophysiology, Communication, Associate, Medical device, Medical imaging, Electrophysiology, Cardiology

People who experience a slower-than-normal heart rate may receive a pacemaker -- a small battery-powered device implanted in the chest that delivers electrical impulses via thin insulated wires, called cardiac leads, that cause the heart muscle chambers to contract to help restore a normal heart rhythm. Unlike traditional pacemakers, leadless pacemakers are implanted directly into the heart through a minimally invasive catheter-based procedure and eliminate the need for cardiac leads. While leadless pacemakers work like traditional pacemakers to regulate heart rate, they offer reduced lead-related complications and a less restrictive recovery period due to the minimally invasive implant procedure.i Yet historically, leadless pacing options have been limited to single-chamber devices because synchronization of two leadless pacemakers has been highly difficult to achieve.

Key Points: 
  • ABBOTT PARK, Ill., Feb. 7, 2022 /PRNewswire/ --Abbott (NYSE: ABT) today announced the world's first patient implants of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i pivotal clinical study.
  • The implant of Abbott's investigational Aveir dual-chamber leadless pacemaker represents a significant technological milestone for leadless pacing technology and is the first to occur around the world within the pivotal trial.
  • The latest milestone for the Aveir DR leadless pacemaker follows recent data showing that Abbott's investigational single-chamber leadless pacemaker Aveir VR met the pre-specified primary endpoints in its pivotal trial.
  • Abbott also designed the Aveir DR leadless pacemaker to be retrievable, so the system can be replaced or retrieved as therapy needs evolve.

Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial

Retrieved on: 
월요일, 2월 7, 2022
People, Department, Time, Cleveland Clinic, Metal electrode leadless face, Heart, Heart rate, PMID, Technology, Patient, NYSE, Parenteral nutrition, Lead, Life, Health, Physician, DDD, Muscle tissue, Cardiac electrophysiology, Communication, Associate, Medical device, Medical imaging, Electrophysiology, Cardiology

ABBOTT PARK, Ill., Feb. 7, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the world's first patient implants of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i™ pivotal clinical study. The implant of Abbott's investigational Aveir™ dual-chamber leadless pacemaker represents a significant technological milestone for leadless pacing technology and is the first to occur around the world within the pivotal trial.

Key Points: 
  • The implant of Abbott's investigational Aveir dual-chamber leadless pacemaker represents a significant technological milestone for leadless pacing technology and is the first to occur around the world within the pivotal trial.
  • Abbott has focused significantly on driving leadless pacing technology that can potentially improve care for more patients battling abnormal heart rhythms.
  • The latest milestone for the Aveir DR leadless pacemaker follows recent data showing that Abbott's investigational single-chamber leadless pacemaker Aveir VR met the pre-specified primary endpoints in its pivotal trial.
  • Abbott also designed the Aveir DR leadless pacemaker to be retrievable, so the system can be replaced or retrieved as therapy needs evolve.